Many molecular-targeted therapies inhibiting signaling pathways of various tyrosine kinase receptors have been developed,and monoclonal antibodies targeting human epidermal

growth factor receptor 2 or vascular endothelial growth factor receptor 2 have become standard therapy for GC.Hepatocyte growth factor and its receptor,c-MET(MET),play key roles in tumor growth through activated signaling pathways from receptor in GC cells.Genomic amplification of MET leads to the aberrant activation found in GC tumors and is related to survival in patients with GC.This review discusses the clinical significance of MET in GC and examines MET as a potential therapeutic target GPCR Compound Library半抑制浓度 in patients 获悉更多 with GC.Preclinical studies in animal models have shown that MET antibodies or smallmolecule MET inhibitors suppress tumor-cell proliferation and tumor progression in MET-amplified GC cells.These drugs are now being evaluated in clinical trials as treatments for metastatic

or unresectable GC.
肺癌高居我国恶性肿瘤病死率的首位,严重威胁着人类的健康,其中非小细胞肺癌(non-small cell lung cancer,NSCLC)包括鳞状细胞癌、腺癌等,与小细胞癌比较其癌细胞生长分裂较慢,扩散转移较晚,约占肺癌的80%~90%。大多数患者就诊时已处于晚期,错失了外科手术的最佳时机,因此,内科治疗成为NSCLC晚期患者的主要治疗方法。近些年来,随着NSCLC相关驱动基因的陆续发现,分子靶向治疗方面的研究取得了质的飞跃,为NSCLC晚期患者提供了新的治疗手段。本文就NSCLC的相关驱动基因进行综述,希望对临床上NSCLC晚期患者的个体化治疗有所裨益。
The last two decades have witnessed a paradigm shift from cytotoxic drugs to targeted therapy in medical oncol?ogy and pharmaceutical innovation. Inspired by breakthroughs in molecular and cellular biology, a

number 什么 of novel synthesized chemical compounds and recombinant antibodies have been developed to selectively target oncogenic signaling pathways in a broad array of tumor types. Although targeted therapeutic agents show impressive clinical eicacy and minimized adverse efects compared with traditional treatments, the challenging drug?resistant issue has also emerged to limit their beneits to cancer patients. In this regard, we aim to improve targeted therapy by present?ing a systematic framework regarding the drug resistance mechanisms and alternative approaches to re?sensitize cancer cells/tissues therapeutically.
Crizotinib是由辉瑞公司开发的,主要用于治疗通过FDA批准的检测方法诊断为间变性淋巴瘤激酶(ALK)阳性的局部晚期或转移的非小细胞肺癌(NSCLC),它是目前惟一个治疗该类疾病的药物。Crizotinib于2011年8月
1.大批新药获批:大量用于治疗癌症和孤儿病的新化学/生物实体获得FDA批准。其中,治疗肺癌的crizotinib和治疗转移性/不可切除性黑色素瘤的vemura fenib被认为是个性化治疗领域的突破。2.